A new blood test developed by Dr. Edward A. Hirschowitz and Dr. Li Zhong could help detect lung cancer in early stages in people who are at high risk for developing the disease. // Lung cancers are a leading cause of cancer death in United States and around the world mainly because of the disease being diagnosed at a later stage. The incidence of lung cancer in Kentucky is 49% higher than the national rate. However, the blood test being developed at the University of Kentucky can soon change things around by making early detection possible.
"Early detection of lung cancer is the key to improving survival," said Zhong, who was the lead author of a study appearing in the July issue of the Journal of Thoracic Oncology that described how the test is 90 percent accurate in correctly predicting non-small-cell lung cancer in patients years before any CT scan can detect it.
Although the researchers have received almost $1.5 million in funding for the development of the test from various sources, they recently received an additional $175,000 National Institutes of Health grant to transform the blood test into a format that real-world clinicians could easily use. And with further studies confirming the reliability of the new format, it could become the first blood test to predict cancer since the prostate specific antigen (PSA) test was introduced in the 1970s.
The multi-biomarker blood test, which works by identifying the body's own immune response to tumors, would help diagnose lung cancer at the earliest stage in those with high risk factors such as age, smoking and genetic history.
Globally, lung cancer is by far the biggest cancer killer, with 10 million people diagnosed each year. In the U.S. alone, the number of lung cancer deaths has risen for each of the past five years to nearly 164,000. The main reason for such a high fatality rate is that 85 percent of lung cancers are found in stages too advanced for best treatm
ent opportunities, Zhong said. Half of all patients die within a year of diagnosis.
For the next two years, the UK research team will collaborate with the private biotechnology company 20/20 GeneSystems to develop the clinical application for the blood test.
"We are hoping in the next several years this test would become available to the public," Zhong said.
Related medicine news :1
. Recommendations for Treatment of Blood Pressue
. Blood Cells Capable of Regenerating Liver
. Blood clots likely in long travel
. Hemochromatosis Patients Blood is Safe 5
. Blood transfusions beneficial after heart attacks 6
. Blood Pressure Drug may slow wasting in burn victims 7
. Levels Of Blood Proteins May Help Heart Disease Care8
. Blood test may identify ovarian cancer9
. A Blood test for suicide risk?10
. Blood Pressure Drugs maintain muscle strength11
. Blood test diagnoses heart failure in short time